Dear Jim,
Thank you so much for sharing your experience and thoughts.
Some patients have indeed experienced tantalizing responses after treatment with CTLA4 antibodies. Let me assure you that many of us in the field keep working hard on figuring out what explains those successes so that, armed with that knowledge, we can extend the benefit to many cancer patients. Experts agree that the way forward requires combinations of immunotherapies. Despite the many obstacles (scientific, regulatory, operational, intellectual property, economic, etc), Pfizer Oncology is moving decisively in that direction.
Warm regards,
Jesus
Jesus Gomez-Navarro, MD
Senior Director, Pfizer Oncology
Immuno-oncology Clinical Lead
No comments:
Post a Comment